Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis (986)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01999192
Recruitment Status : Terminated (Lack of efficacy)
First Posted : December 3, 2013
Results First Posted : August 24, 2017
Last Update Posted : August 24, 2017
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Biotest

Brief Summary:

The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX alone.

The overall study duration is 24 weeks followed by a 24 week extension phase.


Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Tregalizumab Drug: Placebo Phase 2

Detailed Description:

The planned clinical study 986 (TREAT 2b) is a 24-week study in patients with Active rheumatoid arthritis (RA) who have had an inadequate response to Methotrexate (MTX) alone. The main phase of this study is followed by a 24-week extension phase for subjects meeting the respective entry criteria. Patients will be randomized to one of three different Active treatment groups or Placebo. The primary efficacy variable is the proportion of subjects with an ACR20 response after 12 weeks of double blinded treatment with the study medication based on observed cases in the FAS.

At Week 12, all subjects who had a minimum improvement of at least 20% (from baseline) in their tender joint count (TJC) and swollen joint count (SJC) continued on the same treatment. Subjects who had not demonstrated an improvement of at least 20% of TJC and SJC were assessed as non-responders. Non-responders who received placebo were randomized to an active treatment dose in a blinded manner. Non-responders who received active treatment were rolled up to the next highest dose in a blinded manner, apart from those already on the highest dose. These subjects remained on the highest dose.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 321 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)
Study Start Date : October 2013
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose Level 1 Tregalizumab
25mg Tregalizumab s.c. weekly
Drug: Tregalizumab
humanized anti-CD4 mAb
Other Name: BT061

Experimental: Dose Level 2 Tregalizumab
100mg Tregalizumab s.c. weekly
Drug: Tregalizumab
humanized anti-CD4 mAb
Other Name: BT061

Experimental: Dose Level 3 Tregalizumab
200mg Tregalizumab s.c. weekly
Drug: Tregalizumab
humanized anti-CD4 mAb
Other Name: BT061

Placebo Comparator: Placebo
Placebo s.c. weekly
Drug: Placebo
identical end formulation buffer




Primary Outcome Measures :
  1. The Proportion of Subjects Who Achieve an ACR20 at Week 12 Following Treatment With Tregalizumab + MTX Compared With Subjects Treated on Placebo + MTX [ Time Frame: Week 12 ]

    The primary efficacy variable was the proportion of subjects with an ACR20 response after 12 weeks of double-blind treatment with the study medication.

    The analysis of the primary endpoint was performed using observed cases (OC) on the FAS.



Secondary Outcome Measures :
  1. Proportions of Subjects With an ACR 20 Response. [ Time Frame: Week 24 ]
  2. Proportions of Subjects With an ACR 50 & 70 Response. [ Time Frame: Week 12 & Week 24 ]
  3. Proportions of Subjects With an Disease Activity Score DAS28 <2.6 [ Time Frame: Week 12 & Week 24 ]
  4. Proportions of Subjects With Low Disease Activity DAS28 ≤3.2 [ Time Frame: Week 12 & Week 24 ]
  5. ACR Score [ Time Frame: up to 48 weeks ]
  6. Simple Disease Activity Index [SDAI] ≤11 [ Time Frame: week 12 & 24 ]
  7. Clinical Disease Activity Index [CDAI] ≤10 [ Time Frame: week 12 & 24 ]
  8. DAS28 [ Time Frame: up to 48 weeks ]
  9. EULAR Response [ Time Frame: up to 48 weeks ]
  10. ACR Score Individual Components [ Time Frame: up to 48 weeks ]
  11. DAS28 Score Individual Components [ Time Frame: up to 48 weeks ]

Other Outcome Measures:
  1. Pharmacokinetics [ Time Frame: up to 48 weeks ]
    AUC, Cmax, Tmax at baseline, and at Week (W) 2/Visit (V) 4, W4/V5, W8/V7, W12/V8, W24/V10, W3/V122, W48 (end of Treatment [EoT]/ early termination ET), and at follow-up (post EoT/post ET).

  2. Evaluation of Safety, Patient Reported Outcomes & Blood Tests. [ Time Frame: up to 48 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject demonstrates active RA according to the 1987 American College of Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA with functional class I-III for ≥6 months.
  2. Subject receives oral or parenteral MTX treatment for ≥12 weeks (overall), with an unchanged mode of application and stable MTX dose of ≥15 mg per week (or ≥12.5 mg per week in case of MTX intolerance), but no more than the highest locally approved dose for RA, for ≥8 weeks prior to baseline. The dose of MTX is expected to remain stable throughout the study and may be adjusted only for safety reasons. If applicable, the dose of folic acid must be unchanged for ≥8 weeks prior to baseline.
  3. Subject meets the following two criteria at both screening and baseline: − At least 6 swollen joints at 28-joint assessment. − At least 6 tender joints at 28-joint assessment.
  4. Subject has an erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) above the upper limit of normal (ULN) at screening. These tests may be repeated once during the screening period at the discretion of the investigator.
  5. Subject is ≥18 and ≤75 years of age.
  6. Subject has a body mass index ≥18 and ≤35 kg/m².
  7. Subject receives treatment with corticosteroids ≤10 mg prednisone equivalent, stable for at least 4 weeks prior to baseline and during the study, if applicable.
  8. Subject receives treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable for at least 2 weeks prior to baseline and during the study, if applicable.
  9. Female subjects of childbearing potential: has both a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
  10. Subject is judged to be in good general health as determined by the investigator based upon the results of medical history, laboratory profile, physical examination, chest X-ray (within 3 months before screening date is acceptable), and 12−lead electrocardiogram (ECG).
  11. Subject has a cluster of differentiation 4 (CD4) cell count of > 400/µl at screening.

Exclusion Criteria:

  1. Subject has previous exposure to any systemic biologic therapy (e.g., etanercept, adalimumab, rituximab, abatacept, tocilizumab), to Janus kinase (JAK) or spleen tyrosine kinase (SYK) inhibitors, or to Tregalizumab. Previous treatment with an anti-TNF agent is allowed only, if all of the following criteria apply: − treatment was stopped for reasons other than lack of efficacy or adverse events (AEs) − treatment was stopped at least 12 weeks or five half-lives of the compound prior to baseline (whichever is longer), and − the treatment period did not exceed 6 weeks.
  2. Subject received treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) apart from MTX in the 12 weeks prior to baseline, and for DMARD leflunomide in the 24 weeks prior to baseline (except where specific leflunomide wash-out procedures were completed, following applicable guidelines).
  3. Subject has been treated with intra-articular or parenteral administration of corticosteroids in the 4 weeks prior to baseline. Inhaled corticosteroids for stable medical conditions are allowed.
  4. Subject has undergone joint surgery in the 12 weeks prior to baseline (at joints to be assessed within the study) or has undergone major surgery (e.g., abdominal surgery) in the 8 weeks prior to baseline.
  5. Subject has a history of acute inflammatory joint disease of an origin other than RA or subject has any other rheumatic disease other than RA (e.g., mixed connective tissue disease, seronegative spondylarthropathy, psoriatic arthritis, Reiter's syndrome, fibromyalgia, systemic lupus erythematosus or any arthritis with onset prior to age 17 years). However, subjects may have secondary Sjögren's syndrome.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01999192


  Show 84 Study Locations
Sponsors and Collaborators
Biotest
AbbVie
Investigators
Layout table for investigator information
Principal Investigator: Ronald van Vollenhoven, Prof. MD Karolinska Universitetssjukhuset, Solna

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Biotest
ClinicalTrials.gov Identifier: NCT01999192     History of Changes
Other Study ID Numbers: 986_TREAT 2b
2013-000114-38 ( EudraCT Number )
BT986 ( Other Identifier: Biotest AG )
First Posted: December 3, 2013    Key Record Dates
Results First Posted: August 24, 2017
Last Update Posted: August 24, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Biotest:
inadequate response to MTX
Methotrexate
rheumatoid Arthritis
Phase 2b

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors